image
Simulations Plus, Inc. SLP
Healthcare - Medical - Healthcare Information Services - NASDAQ - US
Watchlist
$ 27.79
0.871 %
$ 559 M
Market Cap
77.19
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one SLP stock under the worst case scenario is HIDDEN Compared to the current market price of 27.8 USD, Simulations Plus, Inc. is HIDDEN

SLP Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one SLP stock under the base case scenario is HIDDEN Compared to the current market price of 27.8 USD, Simulations Plus, Inc. is HIDDEN

SLP Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one SLP stock under the best case scenario is HIDDEN Compared to the current market price of 27.8 USD, Simulations Plus, Inc. is HIDDEN

SLP Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart SLP

image
1M -14.0%
6M -8%
1Y -73%
3Y -64%
5Y -98%
All
$38.0$38.0$36.0$36.0$34.0$34.0$32.0$32.0$30.0$30.0$28.0$28.0$26.0$26.0$24.0$24.0$22.0$22.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
70 M REVENUE
17.52%
Growth Rates
1Year 17.52%
3Years 14.64%
5Years 15.56%
7Years 16.43%
10Years 19.84%
6.13 M OPERATING INCOME
-29.73%
Growth Rates
1Year -29.73%
3Years -7.96%
5Years -10.45%
7Years -4.18%
10Years 3.28%
9.95 M NET INCOME
-0.07%
Growth Rates
1Year -0.07%
3Years 0.58%
5Years 3.01%
7Years 8.05%
10Years 12.65%
13.3 M OPERATING CASH FLOW
-39.06%
Growth Rates
1Year -39.06%
3Years -11.48%
5Years 2.74%
7Years 9.90%
10Years 9.64%
-54 M INVESTING CASH FLOW
-732.65%
Growth Rates
1Year -732.65%
3Years -26.37%
5Years -94.16%
7Years -43.27%
10Years -30.07%
-6.56 M FINANCING CASH FLOW
71.78%
Growth Rates
1Year 71.78%
3Years -11.91%
5Years 3.01%
7Years -6.10%
10Years -8.23%
22.4 M REVENUE
18.54%
Growth Rates
1Year 17.52%
3Years 14.64%
5Years 15.56%
7Years 16.43%
10Years 19.84%
2.71 M OPERATING INCOME
2052.38%
Growth Rates
1Year -29.73%
3Years -7.96%
5Years -10.45%
7Years -4.18%
10Years 3.28%
3.07 M NET INCOME
1392.23%
Growth Rates
1Year -0.07%
3Years 0.58%
5Years 3.01%
7Years 8.05%
10Years 12.65%
5.67 M OPERATING CASH FLOW
544.98%
Growth Rates
1Year -39.06%
3Years -11.48%
5Years 2.74%
7Years 9.90%
10Years 9.64%
684 K INVESTING CASH FLOW
121.80%
Growth Rates
1Year -732.65%
3Years -26.37%
5Years -94.16%
7Years -43.27%
10Years -30.07%
-1.55 M FINANCING CASH FLOW
-537.50%
Growth Rates
1Year 71.78%
3Years -11.91%
5Years 3.01%
7Years -6.10%
10Years -8.23%
Balance Sheet Simulations Plus, Inc.
image
Current Assets 39.3 M
Cash & Short-Term Investments 20.3 M
Receivables 9.14 M
Other Current Assets 9.95 M
Non-Current Assets 157 M
Long-Term Investments 0
PP&E 1.84 M
Other Non-Current Assets 155 M
10.30 %4.65 %5.06 %79.06 %Total Assets$196.6m
Current Liabilities 12.1 M
Accounts Payable 602 K
Short-Term Debt 505 K
Other Current Liabilities 11 M
Non-Current Liabilities 2.14 M
Long-Term Debt 531 K
Other Non-Current Liabilities 1.61 M
4.24 %3.55 %77.15 %3.74 %11.32 %Total Liabilities$14.2m
EFFICIENCY
Earnings Waterfall Simulations Plus, Inc.
image
Revenue 70 M
Cost Of Revenue 26.9 M
Gross Profit 43.2 M
Operating Expenses 37 M
Operating Income 6.13 M
Other Expenses -3.82 M
Net Income 9.95 M
80m80m70m70m60m60m50m50m40m40m30m30m20m20m10m10m0070m(27m)43m(37m)6m4m10mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
61.63% GROSS MARGIN
61.63%
Averages
1Year 61.63%
3Years 74.01%
5Years 74.72%
7Years 74.30%
10Years 74.74%
8.76% OPERATING MARGIN
8.76%
Averages
1Year 8.76%
3Years 14.81%
5Years 16.55%
7Years 21.26%
10Years 25.12%
14.22% NET MARGIN
14.22%
Averages
1Year 14.22%
3Years 18.03%
5Years 19.52%
7Years 21.85%
10Years 22.27%
5.46% ROE
5.46%
Averages
1Year 5.46%
3Years 6.11%
5Years 6.04%
7Years 11.57%
10Years 14.48%
5.06% ROA
5.06%
Averages
1Year 5.06%
3Years 5.68%
5Years 5.60%
7Years 9.66%
10Years 11.44%
2.66% ROIC
2.66%
Averages
1Year 2.66%
3Years 4.02%
5Years 4.12%
7Years 9.38%
10Years 11.73%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Simulations Plus, Inc.
image
18m18m16m16m14m14m12m12m10m10m8m8m6m6m4m4m2m2m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 9.95 M
Depreciation & Amortization 5.66 M
Capital Expenditures -566 K
Stock-Based Compensation 6.54 M
Change in Working Capital -4.21 M
Others -9.72 M
Free Cash Flow 12.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Simulations Plus, Inc.
image
Wall Street analysts predict an average 1-year price target for SLP of $56.4 , with forecasts ranging from a low of $47 to a high of $67 .
SLP Lowest Price Target Wall Street Target
47 USD 69.13%
SLP Average Price Target Wall Street Target
56.4 USD 102.95%
SLP Highest Price Target Wall Street Target
67 USD 141.09%
Price
Max Price Target
Min Price Target
Average Price Target
70706565606055555050454540403535303025252020Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.06 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.250.250.200.200.150.150.100.100.050.050.000.000.050.050.050.060.060.060.060.060.060.060.050.050.050.060.060.060.060.060.060.060.050.050.050.060.060.060.060.060.060.060.050.200.050.200.060.210.060.240.060.240.060.240.060.240.060.240.060.240.1820152015201620162017201720182018201920192020202020212021202220222023202320242024
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Simulations Plus, Inc.
image
Sold
0-3 MONTHS
1.7 M USD 1
3-6 MONTHS
1.83 M USD 2
6-9 MONTHS
1.86 M USD 3
9-12 MONTHS
2.49 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Simulations Plus Releases ADMET Predictor® 13 RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of ADMET Predictor® 13, its flagship machine learning (ML) modeling platform for the design, optimization, and selection of new molecules during various stages of drug discovery. ADMET Predictor 13. businesswire.com - 2 weeks ago
SLP Advances Predictive Toxicology With DILIsym 11: Shares to Benefit? Simulations Plus unveils DILIsym 11, an upgraded version of its flagship QST platform to advance predictive toxicology and pediatric liver assessment safety. zacks.com - 1 month ago
Simulations Plus Releases DILIsym® 11 RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of DILIsym® 11, the latest version of its flagship quantitative systems toxicology (QST) platform. “Advancing toxicology research and improving the prediction of drug-induced liver injury (DILI) are. businesswire.com - 1 month ago
Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced its support of the U.S. Food and Drug Administration's (FDA) recently announced roadmap for reducing animal testing through the use of new approach methodologies (NAMs). Simulations Plus has long provided the i. businesswire.com - 1 month ago
Simulations Plus: Benefiting From FDA Modernization And AI Simulations Plus, Inc. offers AI-based software tools for drug discovery and optimization, significantly reducing R&D time and costs for pharmaceutical research. SLP's diverse software portfolio, including GastroPlus and ADMET Predictor, and consulting services position it as a comprehensive partner in biotech development. Favorable regulatory changes by the FDA towards AI and non-animal testing methods boost SLP's market potential, despite its current high valuation. seekingalpha.com - 2 months ago
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday? The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing. benzinga.com - 2 months ago
Simulations Plus: I See Promising Growth, But I'm Staying Neutral Simulations Plus, Inc. excels with its AI-driven biosimulation platforms, aiding drug development, but faces challenges with margin erosion and cash flow pressures. Despite strong revenue growth and promising pipeline expansions, operational inefficiencies and rising costs raise concerns about near-term profitability. Management's ability to convert backlog into profitable revenue and stabilize margins is crucial for long-term shareholder value. seekingalpha.com - 2 months ago
SLP's Q2 Earnings Top, Sales Up Y/Y Despite Industry Headwinds Simulations Plus' fiscal Q2 2025 performance gains from its strong software solutions and services portfolio amid limited customer funding. zacks.com - 2 months ago
Simulations Plus, Inc. (SLP) Q2 2025 Earnings Call Transcript Simulations Plus, Inc. (NASDAQ:SLP ) Q2 2025 Earnings Conference Call April 3, 2025 5:00 PM ET Company Participants Lisa Fortuna - IR, Financial Profiles Shawn O'Connor - CEO Will Frederick - CFO & COO Conference Call Participants David Larsen - BTIG Scott Schoenhaus - KeyBanc Capital Markets Matt Hewitt - Craig-Hallum Christine Rains - William Blair Jeff Garro - Stephens Constantine Davies - Citizen Operator Greetings, and welcome to the Simulations Plus Second Quarter Fiscal 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 2 months ago
Simulations Plus (SLP) Tops Q2 Earnings and Revenue Estimates Simulations Plus (SLP) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.20 per share a year ago. zacks.com - 2 months ago
Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its second quarter fiscal 2025, ended February 28, 2025. Second Quarter 2025 Financial Highlights (as compared to second quarter 2024) Total revenue increased 23% to $22.4 million Software. businesswire.com - 2 months ago
Simulations Plus Gears Up for Q2 Earnings: What's in the Offing? SLP's fiscal Q2 2025 performance is likely to have benefited from continued momentum across its Software and Services segments amid budget constraints. zacks.com - 2 months ago
8. Profile Summary

Simulations Plus, Inc. SLP

image
COUNTRY US
INDUSTRY Medical - Healthcare Information Services
MARKET CAP $ 559 M
Dividend Yield 0.00%
Description Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Contact 42505 Tenth Street West, Lancaster, CA, 93534-7059 https://www.simulations-plus.com
IPO Date June 18, 1997
Employees 243
Officers Ms. Tanya Marvin Marketing Manager Dr. Bud Nelson J.D., Ph.D. Vice President of Corporate Counsel & Personal Data Protection Officer Mr. Steven Chang President of Quantitative Systems Pharmacology Mr. Daniel Szot Chief Revenue Officer Mr. Josh Fohey Senior Vice President of Operations Ms. Jill Fiedler-Kelly M.S. President of Clinical Pharmacology & Pharmacometrics Solutions Mr. John Anthony DiBella M.S. President of PBPK & Cheminformatics Solutions Ms. Lindsay Luke Vice President of Human Resources Ms. Jennifer Presnell Accounting Manager Ms. Viera Lukacova Ph.D. Chief Science Officer